微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 20.7% | -13.68% | -13.6% | 131/159 | 31.9% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 23.96% | -2.81% | 9.82% | 132/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 21.82% | -5.93% | -2.79% | 137/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 22.45% | 3.42% | -6.41% | 138/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 23.98% | -2.65% | -2.72% | 132/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.65% | 11.1% | 6.29% | 133/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 23.2% | 4.19% | 6.87% | 135/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 21.71% | 0.79% | -11.91% | 136/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 24.64% | 5.35% | 11.03% | 129/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 22.19% | -7.22% | -0.32% | 141/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 22.26% | -10.62% | 3.39% | 133/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 21.53% | -12.91% | -7.93% | 139/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 23.39% | -12.76% | -2.22% | 130/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 23.92% | 2.62% | -3.97% | 137/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 24.91% | 14.89% | 0.73% | 123/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 24.73% | 16.89% | -7.77% | 132/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 26.81% | 26.47% | 15.02% | 112/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 23.31% | -17.59% | 7.52% | 133/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 21.68% | -23.15% | 2.48% | 113/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 21.15% | -27.25% | -0.2% | 125/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 21.2% | -28.25% | -25.05% | 105/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 28.28% | -9.2% | 0.26% | 122/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 28.21% | -9.15% | -3% | 97/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 29.08% | -6.27% | -1.57% | 103/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 29.54% | -7.6% | -5.16% | 96/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 31.15% | 14.13% | 0.32% | 114/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 31.05% | 22.32% | 0.09% | 88/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.02% | 23.83% | -2.96% | 92/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 31.97% | 28.96% | 17.15% | 84/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 27.29% | 16.18% | 7.51% | 110/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 25.38% | 12.68% | 1.32% | 88/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 25.05% | 16.11% | 1.05% | 93/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 24.79% | 30.98% | 5.54% | 78/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 23.49% | 19.28% | 4.28% | 104/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 22.53% | 21.69% | 4.4% | 74/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 21.58% | 12.37% | 13.99% | 85/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 18.93% | -1.44% | -3.89% | 75/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 19.69% | 10.21% | 6.39% | 97/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 18.51% | 15.57% | -3.6% | 71/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 19.2% | 16.25% | -0.01% | 76/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 19.2% | 18.01% | 7.47% | 67/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |